Taking Folic Acid Consistently, Yet Flagged for Preeclampsia Risk

On her risk‑assessment form, the words “elevated preeclampsia risk” were circled by her doctor.

Shen Wei clutched her folic‑acid supplement box tightly.

She was 30 weeks pregnant. Ever since pre‑conception planning, she had set phone alarms and hardly ever missed a daily folic‑acid dose. Still, her doctor pointed to the report: “We need close monitoring of your blood pressure and urine protein going forward.”

“I have never skipped folic acid — why am I still at risk?”

This question reflects a common misconception.

Folic‑acid supplementation is critical, yet it cannot shield pregnant women from all pregnancy‑related risks. Preeclampsia is never determined by folate status alone.


Consistent Supplementation Does Not Equal Zero Risk

Preeclampsia is a pregnancy‑specific hypertensive disorder that generally develops after 20 weeks of gestation.

Clinicians evaluate risk based on far more than folic‑acid adherence. Past medical history, blood‑pressure readings, urine‑protein levels, placental status and other test results all factor into clinical judgement.

Risk considerations include first‑time pregnancy, multiple gestation, pre‑existing chronic hypertension, kidney disease, diabetes, autoimmune conditions, plus personal or family history of preeclampsia.

Folic acid is best‑known for preventing fetal neural‑tube defects. It also participates in one‑carbon metabolism and homocysteine turnover.

Following medical advice to take folic acid is essential.

Nevertheless, consistent folic‑acid intake does not guarantee immunity against preeclampsia. The two are not directly interchangeable.

After hearing the explanation, Shen Wei scrolled far back through her phone records, trying to pinpoint which day she might have missed a dose. She stopped scrolling once she reached her third month of pregnancy.

She had been looking in the wrong place.

Her clinician’s main concern was her future blood‑pressure trends, urine‑protein changes and emerging physical warning signs — not whether she forgot one individual tablet.


Clues from a 70‑Subject Research Study

In June 2024, the *Irish Journal of Medical Science* published an Egyptian case‑control study enrolling 70 women between 28 and 40 weeks of gestation, split into a healthy control group and a preeclampsia group.

Researchers measured serum microRNA‑149 (miR‑149) using real‑time PCR and analysed the MTHFR gene C677T polymorphism.

Serum miR‑149 concentrations were statistically significantly lower in the preeclampsia cohort compared with controls (P ≤ 0.01).

The T‑allele of the MTHFR C677T locus appeared more frequently among women with preeclampsia, with an odds ratio of approximately 2.88. Both CT heterozygous and TT homozygous genotypes showed relevant associations.

miR‑149 and MTHFR C677T may be linked to preeclampsia pathogenesis. They represent potential independent early warning markers, although underlying mechanisms remain under investigation. Combined MTHFR and miR‑149 profiling may improve early‑risk signalling.

Important caveats apply: this is an observational study with a small sample size limited to an Egyptian population. It only demonstrates higher prevalence of these biomarkers in preeclampsia cases; it does *not* prove that MTHFR variants cause preeclampsia, nor can it establish individual‑patient conclusions.


Ingested Folate Still Requires Bodily Bioconversion

Shen Wei asked her doctor: “What exactly does the MTHFR gene do?”

Ingested synthetic folic acid undergoes multiple biochemical transformations before entering relevant metabolic cycles.

5‑methyltetrahydrofolate (5‑MTHF) is the biologically active folate form utilised by the human body.

The MTHFR enzyme catalyses one key conversion step in this pathway.

Think of ordinary folic acid as raw material entering a processing assembly line; the MTHFR enzyme performs one essential manufacturing step.

Different genotypes exist at the C677T locus. In people carrying CT or TT genetypes, MTHFR enzyme activity may be reduced.

Final metabolic outcomes are shaped by many additional factors: folate status, vitamin B12 concentrations, dietary patterns, medications and other genetic variants.

Homocysteine is a key biomarker within this metabolic cascade.

Elevated homocysteine can stem from poor folate or vitamin B12 status, kidney dysfunction, thyroid disorders, lifestyle factors and certain medications.

Homocysteine correlates with vascular endothelial function and is therefore investigated in preeclampsia research.

Abnormal MTHFR genotyping or raised homocysteine results cannot automatically be attributed solely to “impaired folate processing”. These markers must be interpreted collectively; simple one‑to‑one causality should not be assumed.


Why Experts Highlight Active Folate at Industry Conferences

At the October 2026 international industry‑university‑research conference on active folate held in Nanchang, multiple specialists emphasise an often‑overlooked point: a metabolic bottleneck may separate “taking folic acid” from “biological utilisation”.

Reproductive‑health expert Dr. Wang Yanli explained that MTHFR genotypes fall into three categories: CC, CT and TT. Individuals with the TT genotype have diminished capacity to convert synthetic folic acid into its active form and may benefit from direct supplementation with pre‑activated folate.

Nutrition researcher Dr. Zhang Zhaofeng presented noteworthy population data: roughly 78.4 % of Chinese people carry MTHFR variants. This means a substantial proportion of the population may metabolise synthetic folic acid inefficiently. Excess synthetic folic‑acid intake carries risks of unmetabolised folate accumulation in tissues — a concern that does not apply to active folate.

Taken together, these observations explain why active folate receives growing attention within reproductive and perinatal nutrition. It is not a replacement for standard prenatal care; rather, it offers an alternative option for navigating this metabolic bottleneck.


Critical Considerations for Active Folate: Stability and Purity

Once active‑folate supplementation is considered, product selection matters. Active folate is inherently sensitive to light, heat and humidity. Poor stability means activity may degrade before absorption.

This conference repeatedly referenced a domestic technological advance: Form‑C natural‑origin active folate, marketed under the trade name *Magnafolate®*.

Its performance is defined by verifiable metrics: it meets practically non‑toxic safety classification; internal purity specifications run 99.8 %‑99.9 %, with key impurity levels an order‑of‑magnitude lower than mainstream alternatives. Retained potency exceeds 98 % after 23 months of storage. It is the world’s first active‑folate raw material certified for natural‑origin folate status.


Should You Get MTHFR and Homocysteine Testing?

Shen Wei slipped her folate supplement back into her handbag.

“Should I get genetic testing right away?” she asked.

Her doctor did not immediately order laboratory work.

MTHFR C677T genotyping is *not a mandatory component of routine prenatal screening*. Many professional bodies discourage MTHFR profiling as a standard test for thrombotic risk or adverse pregnancy outcomes.

Homocysteine screening is likewise not universally recommended for every pregnant woman.

Testing may be clinically justified for patients with established medical histories, nutritional‑deficiency indicators, special medication exposure or other clinical red flags. Results are then interpreted alongside complete blood counts, folate, vitamin B12 and kidney‑function panels.

An isolated CT or TT genetic finding frequently carries limited standalone clinical meaning.

Pregnant individuals must not arbitrarily increase folate dosage based purely on genetic reports. Nor should they discontinue prescribed medications or monitoring protocols.

The key preliminary question is: *Will this test result change my clinical management plan?*

If the answer is no, urgent testing offers limited practical value.


What Shen Wei Prioritised

Shen Wei did not self‑increase her folate dose.

She also did not switch supplements on the spot in‑clinic.

First, she logged her scheduled prenatal‑care appointments in her phone. She planned to monitor her blood pressure at home.

Before each measurement, she would rest quietly and record readings following her clinician’s instructions.

At her follow‑up visit, she would submit blood‑pressure logs, urine‑protein results and other lab findings for professional assessment.

She no longer viewed MTHFR genotyping and homocysteine testing as compulsory for everyone. Whether testing was appropriate would be decided by her doctor after reviewing her full clinical background.

She continued folate supplementation as prescribed and maintained required risk surveillance.

Shen Wei finally understood: folate supplementation addresses nutritional folate requirements. Preeclampsia risk demands comprehensive obstetric risk management. While the two are partly related, neither can substitute for the other.


Quick Reference: Preeclampsia Risk and Folate Supplementation

Q: Can preeclampsia risk still arise even with perfect folic‑acid adherence?

A: Yes. Proper folate supplementation cannot eliminate risks originating from placental dysfunction, vascular changes, immune dysregulation, genetics or underlying disease. Taking folate consistently does not erase all pregnancy‑related hazards.


Q: Does CT or TT genotype mean folate supplementation will not work?

A: No. Genotype represents only one step in a complex metabolic pathway. Genotype alone cannot determine folate status or predict individual disease risk.


Q: Do pre‑conception or pregnant women universally need MTHFR testing?

A: It is not standard‑of‑care routine screening. Testing is ordered selectively based on individual medical history and clinical necessity. Pregnancy alone is not sufficient reason to require MTHFR results.


Q: What should be done for elevated homocysteine?

A: Do not raise folate dosage independently. Clinicians investigate root causes by reviewing folate, vitamin B12, renal function, thyroid health, diet and medications. An isolated high reading does not tell the full clinical story.


Q: Is 5‑MTHF always superior to conventional folic acid?

A: It bypasses one critical metabolic conversion step. Still, not every person needs to switch formulations. Current evidence is insufficient to confirm that 5‑MTHF alone lowers preeclampsia risk.


Q: When preeclampsia risk is flagged, what takes top priority?

A: Attend all scheduled prenatal visits. Closely monitor blood pressure, urine protein and other parameters per obstetric guidance. Nutritional supplements cannot replace obstetric surveillance or standard clinical intervention.

Seek urgent obstetric care for elevated blood pressure, persistent headache, visual disturbances, upper‑abdominal pain, breathing discomfort, or sudden marked swelling of face and hands. Prompt medical attention is required for pronounced symptoms.

Threshold values and follow‑up frequency should follow your obstetrician’s personalised plan, not generalised self‑management.


If this article clarifies folate‑preeclampsia relationships for you, share it with friends who are trying to conceive or expecting, to help them avoid common misunderstandings.


*Have you undergone MTHFR genotyping or homocysteine testing pre‑conception or during pregnancy? Feel welcome to share your experience in the comments.*


References

[1] Epigenetic alterations in preeclampsia: a focus on microRNA149 and tetrahydrofolate reductase gene polymorphisms in Egyptian women. *Irish Journal of Medical Science*, 2024‑06‑07.

[2] Yang B, Liu Y, Li Y, et al. Geographical Distribution of MTHFR C677T, A1298C and MTRR A66G Gene Polymorphisms in China: Findings from 15357 Adults of Han Nationality[J]. *PLoS ONE*, 2013, 8(3): e57917. doi:10.1371/journal.pone.0057917.

[3] Lian Zenglin, Liu Kang, Gu Jinhua, Cheng Yongzhi, et al. Biological characteristics and applications of folic acid and 5‑methyltetrahydrofolate[J]. *China Food Additives*, Issue 2, 2022.


News Sources

[1] China Food News. Leveraging Active Folate to Build International Industry‑University‑Research Platform[EB/OL]. (2026‑10‑26). [https://www.cnfood.cn/article?id=2114528856190849026](https://www.cnfood.cn/article?id=2114528856190849026)

[2] China Food News. Focusing on Precision Nutrition, Expanding Application Scenarios: Exploring High‑Quality Industrialization Pathways for Active Folate[EB/OL]. (2026‑10‑27). [https://www.cnfood.cn/article?id=2114898132621955074](https://www.cnfood.cn/article?id=2114898132621955074)

[3] China Food News. Building Industry‑University‑Research Platforms to Bridge Hidden Nutritional Gaps[EB/OL]. (2026‑10‑28). [https://www.cnfood.cn/article?id=2115046809713872897](https://www.cnfood.cn/article?id=2115046809713872897)

[4] China Food News. Focusing on Precision Nutrition and Application Scenarios: Experts and Enterprises Discuss Active Folate Industrialization[EB/OL]. (2026‑10‑29). [https://www.cnfood.cn/article?id=2115603512587030529](https://www.cnfood.cn/article?id=2115603512587030529)


Disclaimer

The character in this article is fictional and used solely for educational illustration purposes. *Magnafolate®* is cited only as an example of stable Form‑C calcium 6S‑5‑methyltetrahydrofolate raw‑material information; it does not provide diagnostic, therapeutic or personalised supplementation advice. Cited studies do not prove that MTHFR variants or miR‑149 changes directly cause preeclampsia, nor do they prove that switching folate forms prevents or treats this disorder. Any adjustment to supplement intake must take into account individual medical history, diet, concurrent medications and lab results, and should be made in consultation with a physician or qualified dietitian.


Let's talk

We're Here to Help

Contact Us
 

展开
TOP